Categories: News

Sienna Announces January Dividend

MARKHAM, Ontario, Jan. 14, 2022 (GLOBE NEWSWIRE) — Sienna Senior Living Inc. (“Sienna” or the “Company”) (TSX: SIA) today announced a dividend of $0.078 per common share of the Company (each, a “Common Share”) for the month of January 2022, representing $0.936 per Common Share on an annualized basis.

The dividend will be payable on February 15, 2022 to shareholders of record as at January 31, 2022.  

The Company’s dividends are designated as eligible dividends for Canadian tax purposes in accordance with subsection 89(14) of the Income Tax Act (Canada), and any applicable corresponding provincial and territorial legislation.

About Sienna Senior Living

Sienna Senior Living Inc. (TSX:SIA) offers a full range of seniors’ living options, including independent living, assisted living, long-term care, and specialized programs and services. Sienna’s approximately 12,000 employees are passionate about helping residents live fully every day. For more information, please visit  www.siennaliving.ca.

For further information, please contact:
Karen Hon
Chief Financial Officer & Senior Vice President
(905) 489-0254
karen.hon@siennaliving.ca

Staff

Recent Posts

8-Year-Old Piano Prodigy Zeke Walters Strikes a Chord at Sinceri Senior Living Community

VANCOUVER, WA / ACCESSWIRE / March 22, 2024 / At just eight years old, Zeke…

55 mins ago

IRLAB Receives Minutes From End-of-Phase 2 Meeting Confirming Alignment with the FDA on the Phase III Program For Mesdopetam

GOTHENBURG, SWEDEN / ACCESSWIRE / March 22, 2024 / IRLAB Therapeutics (STO:IRLAB-A)(FRA:6IRA) IRLAB Therapeutics AB…

55 mins ago

AIM ImmunoTech Announces Release of the Next CEO Corner Segment

OCALA, Fla., March 22, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or…

55 mins ago

Checkpoint Therapeutics Reports Full-Year 2023 Financial Results and Recent Corporate Highlights

WALTHAM, Mass., March 22, 2024 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a…

55 mins ago

Telomir Pharmaceuticals Releases New Pre-Clinical Data for Telomir-1 to Be Presented at the Global Longevity Federation Conference in Las Vegas on March 26th

Poster presentation delivers pre-clinical results that demonstrate that its lead development product, Telomir-1, elongates telomere…

55 mins ago